Dishman Carbogen Amcis Q1 FY27: A soft quarter shaped by CDMO deferrals and forex, with a second-half reset in focus

Dishman Carbogen Amcis Limited reported a weaker start to FY27, with consolidated revenue from operations of INR 677.6 crores in Q1 FY27, down 4.3% year on year. The quarter was heavily impacted by the deferment of CDMO revenue and a notional foreign exchange loss, which compressed EBITDA margin to 8.9% from 19.9% in the comparable quarter last year. Profit after tax turned negative at INR 57.9 crores.

Management framed the quarter as timing-led rather than demand-led. A customer-requested rescheduling of project deliverables worth roughly CHF 10 million was cited as the key reason for lower CDMO revenue recognition in Q1, with execution now expected in the second half of FY27. The company also pointed to a notional forex loss of INR 11.7 crores linked to currency movement between the US dollar and Swiss franc.

Segment mix: CDMO dipped, Marketable Molecules offset part of the decline

The headline revenue decline masked a meaningful mix shift. CDMO revenue fell 12.6% year on year to INR 534.4 crores, while Marketable Molecules rose 48% to INR 143.3 crores, driven by higher cholesterol sales.

While Marketable Molecules supported topline stability, margins also moved with the mix. The CDMO segment EBITDA margin fell to 6.3% as fixed costs could not be flexed down with the revenue deferment, and forex effects added further pressure. Marketable Molecules margin also normalized to 18.6% from 32.4% last year, with management attributing the change to a higher cholesterol share versus Vitamin D analogues.

Execution levers: tech transfers, commercial buildout, and the integrated CDMO pitch

Beyond the quarter’s volatility, management commentary focused on medium-term execution levers. A key theme was increased operational integration between Carbogen Amcis and Dishman India, with multiple technology transfers from Switzerland to India highlighted. The COO said a commercial contract has already been signed with a US company to transfer a legacy project from Switzerland to the Bavla site, with completion expected within FY27. A second major legacy tech transfer has also been approved by a prominent Swiss multinational and initiated, with three additional projects in advanced discussions.

The rationale was explicit: customers benefit from lower pricing while maintaining quality, and the group aims to improve margins through India-based manufacturing for suitable commercial products. Management also described this as active life cycle management of commercial products.

The company also emphasized commercial strengthening. A new Global Chief Commercial Officer was appointed, with management noting ongoing recruitment across Europe and the US and planned additions in inside sales and prospecting roles. The stated objective was to increase prospecting and improve closure rates on opportunities, while leveraging the group’s integrated offering across development, drug substance, and drug product.

In ADC and bioconjugation, the company reiterated its integrated workflow spanning drug linker, bulk drug substance, and drug product manufacturing. On the call, management indicated ADC-related revenue of roughly INR 150 crores for the quarter, including linkers and related components.

Balance sheet and financing: refinancing plan aims to lower India cost of debt

Net debt excluding lease liabilities was disclosed at CHF 153.6 million as of June 30, 2026, up from CHF 146.8 million at March 31, 2026. Investors questioned the finance cost burden, and management responded with a refinancing plan in progress.

The CFO said the company has obtained shareholder approval for the promoter entity to raise foreign currency funds up to CHF 200 million and infuse them into the Indian entity as an external commercial borrowing. The disclosed all-in interest cost is 4% with a 10-year tenor, and management expects execution in about 60 to 90 days, subject to banking diligence and documentation across jurisdictions. The stated purpose is to prepay high-cost India debt and also support future capex or working capital needs.

On guidance, management reiterated that FY27 should see single-digit consolidated revenue growth, with EBITDA margin expected to be similar to FY26 and possibly slightly higher. For the India entity, the CFO guided to 30 to 35% revenue growth in FY27 with operating margin around 10%. For FY28 and FY29, management expects more than 10% revenue growth supported by double-digit growth in the France entity and India operations, with EBITDA margin targeted closer to 25 to 26%, which management described as levels achieved before EDQM-related issues.

Takeaways

Dishman Carbogen Amcis entered FY27 with a weak quarter, but management has pointed to clear, verifiable drivers: deferred CDMO deliveries and forex impacts. The near-term monitorable items are whether the rescheduled CDMO work is executed in the second half and whether the expanded commercial organization improves conversion. The medium-term story rests on tech transfers to India, scale-up of the France drug product footprint, and debt refinancing that could reduce the cost of capital and improve earnings resilience.